EUVIMEDEUVIMED entdecken
Crossref

Novel 2-Anilinoquinazoline derivatives as apoptosis-inducing agents in drug-resistant NSCLC cells: Integrating biological and computational evaluation

Jeevitha Sivam, Maelinda Daker, Marini Marzuki, Aisha Yusuf Lawal, Sze Wei Leong, Zarif Mohamed Sofian, Suzita Mohd Noor, Muhammad Ameerullah Sahudin, Azhar Ariffin, Ajantha Sinniah, Anwar Norazit, Muhammad Kumayl Abdulwahab

Bioorganic Chemistry · 2026

DOI: 10.1016/j.bioorg.2026.109702 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Jeevitha Sivam und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science, Universiti Malaya, 50603 Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Quinazolines, Apoptosis, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: University of Malaya, Malaysia Ministry of Higher Education, Ministry of Health Malaysia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for approximately 85% of all cases. Despite widespread use, the limited durability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) highlights the need for strategies that suppress tumour proliferation and restore apoptosis in resistant NSCLC. In this study, a series of eleven 2-anilinoquinazoline derivatives was synthesised to identify new scaffolds capable of restoring apoptotic signalling in drug-resistant NSCLC cells. Among these, JS04 emerged as the most potent derivative, exhibiting antiproliferative activity with IC₅₀ values of 8.11 ± 0.43 μM and 11.58 ± 1.68 μM against H1975 (EGFR-TKI resistant) and A549 (EGFR-independent) cell lines, respectively, outperforming gefitinib. Real-time impedance (xCELLigence) and flow cytometry analyses demonstrated that JS04 induced rapid, dose-dependent apoptosis, achieving 74% apoptotic cell death at 20 μM, substantially higher than erlotinib (13%). Proteome profiling confirmed activation of both intrinsic (downregulation of Bcl-2, Bcl-xL, and survivin) and extrinsic (upregulation of TRAIL R2/D5) apoptotic pathways, accompanied by G₂/M phase cell cycle arrest comparable to osimertinib. Zebrafish embryo assays revealed a favourable safety profile (LC₅₀ = 38.42 ± 3.96 μM). Computational studies, molecular docking and 100 ns molecular dynamics simulations indicated that JS04 forms stable hydrogen bonds with hinge region residues MET793 and GLN791, and exhibits strong binding affinity toward the EGFRL858R/T790M kinase. Collectively, these findings position JS04 as a promising quinazoline-based lead candidate that effectively triggers dual apoptotic mechanisms, selectivity toward H1975 cells, and demonstrates early indications of safety, warranting further biochemical validation, structure-activity optimisation, and in vivo efficacy evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinazolinesApoptosisAntineoplastic AgentsCarcinoma, Non-Small-Cell LungAniline CompoundsLung NeoplasmsDrug Resistance, NeoplasmHumansAnimalsDrug Screening Assays, AntitumorCell ProliferationZebrafishStructure-Activity RelationshipMolecular Docking SimulationMolecular StructureCell Line, TumorProtein Kinase InhibitorsDose-Response Relationship, DrugErbB Receptors

Stichwörter der Autor:innen

2-Anilinoquinazoline derivativesAntiproliferative activityApoptosis inductionComputational predictionZebrafish in vivo toxicity

Substanzen

QuinazolinesAntineoplastic AgentsanilinoquinazolineAniline CompoundsProtein Kinase InhibitorsErbB Receptors

Autor:innen und Institutionen

  • Department of Chemistry, Faculty of Science, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
  • Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, 40170 Shah Alam, Selangor, Malaysia.
  • Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
  • Department of Biomedical Science, Faculty of Medicine, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
  • Department of Pharmacology, Faculty of Medicine, Universiti Malaya, 50603 Kuala Lumpur, Malaysia. Electronic address: ajantha.sinniah@um.edu.my.
  • Department of Biomedical Science, Faculty of Medicine, Universiti Malaya, 50603 Kuala Lumpur, Malaysia. Electronic address: anwar.norazit@um.edu.my.

Förderung

  • University of Malaya
  • Malaysia Ministry of Higher Education
  • Ministry of Health Malaysia

Zitieren

APA

Sivam, J., Daker, M., Marzuki, M., Lawal, A. Y., Leong, S. W., Sofian, Z. M., Noor, S. M., Sahudin, M. A., Ariffin, A., Sinniah, A., Norazit, A., & Abdulwahab, M. K. (2026). Novel 2-Anilinoquinazoline derivatives as apoptosis-inducing agents in drug-resistant NSCLC cells: Integrating biological and computational evaluation. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.109702

Vancouver

Sivam J, Daker M, Marzuki M, Lawal AY, Leong SW, Sofian ZM, et al. Novel 2-Anilinoquinazoline derivatives as apoptosis-inducing agents in drug-resistant NSCLC cells: Integrating biological and computational evaluation. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.109702

BibTeX
@article{Sivam2026,
  author = {Sivam, Jeevitha and Daker, Maelinda and Marzuki, Marini and Lawal, Aisha Yusuf and Leong, Sze Wei and Sofian, Zarif Mohamed and Noor, Suzita Mohd and Sahudin, Muhammad Ameerullah and Ariffin, Azhar and Sinniah, Ajantha and Norazit, Anwar and Abdulwahab, Muhammad Kumayl},
  title = {Novel 2-Anilinoquinazoline derivatives as apoptosis-inducing agents in drug-resistant NSCLC cells: Integrating biological and computational evaluation},
  journal = {Bioorganic Chemistry},
  year = {2026},
  doi = {10.1016/j.bioorg.2026.109702}
}
Kostenlos starten →